Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 642-646

  Cooper, Nichola ^a   Evangelista, Maria Laura ^b   Amadori, Sergio ^c   Stasi, Roberto ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Immune thrombocytopenic purpura; Rituximab; Splenectomy

Indexed keywords

RITUXIMAB;

ANGIONEUROTIC EDEMA; BRONCHOSPASM; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; DEATH; FEVER; HIGH RISK PATIENT; HUMAN; HYPOTENSION; HYPOXIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INCIDENCE; INFECTION; PRIORITY JOURNAL; REVIEW; RIGOR; SAFETY; SPLENECTOMY; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENECTOMY;

EID: 34848858004     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282c8ca50     Document Type: Review

References (27)

1. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33. This is a systematic review of studies enrolling five or more patients with chronic ITP treated with rituximab. It included 19 eligible reports on efficacy (313 patients) and 29 on safety (306 patients). Weighted means for complete response and overall response with rituximab were 43.6% and 62.5%, respectively. Responses lasted from 2 to 48 months. Nine patients (2.9%) died.
2. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69:95-100.
3. Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003; 88:538-546.
4. Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005; 90:1273-1274.
5. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125:232-239.
6. Penalver FJ, Jimenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006; 85:400-406. This retrospective study evaluated the effectiveness of rituximab in the treatment of 89 patients with chronic ITP. The unique predictor of a maintained response was to reach a complete response. Heavily treated patients and those with longer ITP duration (>10 years from diagnosis) had a worse response.
7. 9/l during four consecutive weeks, starting in weeks 9 to 12, was achieved by 11 of 36 patients (31%). Rituximab was well tolerated, with manageable infusion-related side effects, but 6% of subjects developed serum sickness.
8. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146:217-221.
9. Patel V, Mihatov N, Cooper N, et al. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year [abstract]. Blood 2006; 108:Abstract 479.
10. Zaja F, Vianelli N, Battista M, et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006; 34:571-572. This retrospective study showed that 15 of 37 patients with chronic ITP treated with rituximab (40.5%) maintained a sustained response, with a projected 2-year relapse-free survival of 61.5%. A significantly higher rate of relapse was evident for patients who had an interval from diagnosis to rituximab longer than 36 months.
11. Godeau B, Fain O, Porcher R, et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study [abstract]. Blood 2006; 108:Abstract 478.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30.html. [Accessed 3 April 2007].
13. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160:1630-1638.
14. Lazdina U, Alheim M, Nystrom J, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003; 84:139-146.
15. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
16. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209-220. This review addresses the risks of hepatitis B virus reactivation following therapy with immunosuppressive agents, including rituximab, in patients with positive hepatitis B serology.
17. Hanbali A, Khaled Y, Ajrouche H, et al. Incidence of hepatitis B reactivation in association with rituximab therapy [abstract]. Blood 2006; 108:Abstract 2766.
18. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623-2634.
19. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79:504-522.
20. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90:72-77.
21. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104:956-960.
22. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97:2549-2554.
23. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122:187-188.
24. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
25. Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002; 2:440-443.
26. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94:909-913.
27. Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122:966-974.